Vasovist is intended for use in evaluating aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease. AIOD occurs when iliac arteries become narrowed or blocked, potentially preventing the sufficient transport of oxygen and blood throughout the body.
Vasovist becomes the first contrast agent to be approved for marketing in the U.S. for use with MR angiography. The agent is already approved for marketing in 34 countries outside the U.S.
Epix reduces its workforce, October 23, 2008
Epix to form technology advisory board, August 14, 2008
Epix's Q2 results show boosted revenues, August 7, 2008
Epix secures equity financing, August 5, 2008
Epix CEO resigns, July 28, 2008
Copyright © 2008 AuntMinnie.com